XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB – Get Free Report) saw a large decline in short interest in May. As of May 29th, there was short interest totaling 9,750 shares, a decline of 49.3% from the May 14th total of 19,218 shares. Based on an average daily volume of 26,934 shares, the short-interest ratio is presently 0.4 days. Currently, 0.6% of the shares of the stock are sold short.
XTL Biopharmaceuticals Stock Performance
Shares of NASDAQ:XTLB opened at $2.13 on Friday. XTL Biopharmaceuticals has a 52 week low of $2.01 and a 52 week high of $10.28. The company’s fifty day moving average is $2.54 and its 200-day moving average is $4.48. The company has a market capitalization of $4.69 million, a PE ratio of -3.33 and a beta of 1.48.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a research note on Thursday, April 2nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.
XTL Biopharmaceuticals Company Profile
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
Further Reading
- Five stocks we like better than XTL Biopharmaceuticals
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for XTL Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XTL Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
